TELA Bio shares jump 14.08% intraday after announcing inducement equity awards for new hires under Nasdaq Rule 5635(c)(4).

TELA Bio surged 14.08% intraday following its announcement of inducement equity grants to newly hired employees under Nasdaq Rule 5635(c)(4). The Compensation Committee approved 30,200 restricted stock units for 17 employees and a 25,000-share option at $1.19 per share, with vesting over four years, as part of employment incentives. This move signals confidence in attracting talent to advance its commercial-stage medical technology initiatives, particularly in soft-tissue reconstruction. While Canaccord Genuity’s price target reduction to $4.00 introduced bearish sentiment, the stock’s sharp intraday rise aligns with positive market reception of the equity awards, which underscore the company’s commitment to growth and innovation.